M1180 Immune Checkpoint Inhibitor Therapy HCPCS Reimbursement

HCPCS Level II code M1180 denotes patients receiving immune checkpoint inhibitor therapy, capturing services related to pharmacotherapy monitoring and management in outpatient oncology settings. This code matters nationally as immune checkpoint inhibitors are a rapidly growing class of cancer therapies with distinct monitoring and management needs, influencing utilization patterns, clinical workflows, and payer coverage considerations across commercial and public plans.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for M1180, typical sites of service, and common billing modifiers. The publication summarizes national benchmarks where available, clarifies coding and billing implications for oncology outpatient care, and highlights relevant policy considerations affecting coverage and claims processing for immune checkpoint inhibitor management.

This executive summary equips revenue cycle managers, oncology billing staff, and policy analysts with a practical reference to the purpose of M1180, payers commonly involved, and the types of information to consult when evaluating claims and coverage for patients on immune checkpoint inhibitors. Data not available in the input is noted where pertinent.

Billing Code Overview

HCPCS Level II code M1180 identifies patients on immune checkpoint inhibitor therapy. The service type for this code is oncology pharmacotherapy monitoring and management, reflecting care related to administration, monitoring, or management of immune checkpoint inhibitor therapies. The typical site of service for services billed with this code is outpatient oncology settings, including infusion centers and clinic-based specialty oncology practices.

Data not available in the input.

Clinical Context

A typical patient is an adult oncology patient receiving immune checkpoint inhibitor therapy (for example, anti–PD-1, anti–PD-L1, or anti–CTLA-4 agents) for advanced or metastatic malignancy such as non–small cell lung cancer, melanoma, renal cell carcinoma, or urothelial carcinoma. The clinical workflow includes baseline assessment, administration of systemic immunotherapy in an outpatient infusion center or oncology clinic, monitoring for immune-related adverse events (irAEs), periodic laboratory surveillance (CBC, CMP, thyroid function), and scheduled follow-up visits for treatment response assessment and toxicity management. Typical site of service is an outpatient hospital infusion center or physician office-based infusion suite. Common clinical encounters include pre-infusion assessment, medication administration visits, urgent evaluation for possible irAEs (dermatologic, gastrointestinal, hepatic, endocrine, pulmonary), and coordination of imaging and specialty referrals as needed. The scenario often involves documentation of the treatment regimen, indication, dosing schedule, informed consent, vital signs and symptom review, medication administration record, and contemporaneous management plans for any documented immune-related toxicities.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when work required to manage complications or perform extensive counseling/documentation related to immunotherapy exceeds usual service.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology-Oncology	Oncologists who prescribe and manage immune checkpoint inhibitors.
`208D00000X`	Medical Oncology	Providers delivering systemic cancer therapy and managing irAEs.
`363A00000X`	Nurse Practitioner	Advanced practice providers who coordinate infusion visits and toxicity management.
`363L00000X`	Physician Assistant	Midlevel providers who assist in outpatient infusion and follow-up care.
`261QM0801X`	Clinical Nurse Specialist	Oncology clinical nurse specialists involved in patient education and management.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C34.90`	Malignant neoplasm of unspecified part of bronchus or lung, unspecified	Non–small cell lung cancer is a common indication for immune checkpoint inhibitors.
`C43.9`	Malignant melanoma, unspecified	Advanced melanoma frequently treated with checkpoint inhibitors.
`C64.9`	Malignant neoplasm of kidney, unspecified	Renal cell carcinoma is an indication for several immune checkpoint inhibitors.
`C67.9`	Malignant neoplasm of bladder, unspecified	Urothelial carcinoma is commonly treated with PD-1/PD-L1 inhibitors.
`Z51.11`	Encounter for antineoplastic chemotherapy	Used to report encounters for administration of systemic antineoplastic agents, including immunotherapy.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial drug	Common code for administration of a single-agent immunotherapy infusion lasting up to one hour.
`96415`	Chemotherapy administration, IV infusion technique; each additional hour (list separately in addition to code for primary service)	Used when immunotherapy infusion extends beyond the initial hour and additional infusion time is billed.
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	Used for therapeutic infusions when immunotherapy administration coding matches this descriptor per payer guidance.
`36415`	Collection of venous blood by venipuncture	Performed for laboratory monitoring (CBC, CMP, endocrine labs) before or during immunotherapy.
`36561`	Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older	Performed when vascular access is required for repeated immunotherapy infusions or if peripheral access is inadequate.

OpenPayer

Summary & Overview

HCPCS M1180: Patients on Immune Checkpoint Inhibitor Therapy